Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 4/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 12/20 | 0.48 |
| ▸ | KLHL20 | Q9Y2M5 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25455285 | 1.00 | PLAU (0.49) | PLAUKLKB1KLHL20KEAP1EPHA2 | |
| SCHEMBL25455804 | 0.96 | PLAU (0.48) | PLAUKLKB1KLHL20KEAP1EPHA2 | |
| SCHEMBL25455211 | 0.96 | PLAU (0.48) | PLAUKLKB1KLHL20KEAP1EPHA2 | |
| SCHEMBL25455257 | 0.94 | EPHA2 (0.46) | PLAUKLKB1KLHL20KEAP1EPHA2 | |
| SCHEMBL25455413 | 0.94 | PLAU (0.55) | PLAUKLKB1KLHL20KEAP1KLK5 | |
| SCHEMBL25455428 | 0.94 | PLAU (0.49) | PLAUKLKB1KLHL20KEAP1KLK5 | |
| SCHEMBL25455271 | 0.93 | PLAU (0.47) | PLAUKLKB1KLHL20EPHA2 | |
| SCHEMBL25459164 | 0.92 | EPHA2 (0.47) | PLAUKLKB1KLHL20EPHA2ST14 | |
| SCHEMBL25455516 | 0.92 | PLAU (0.49) | PLAUKLKB1EPHA2KLK5 | |
| SCHEMBL25457456 | 0.92 | PLAU (0.55) | PLAUKLKB1KLHL20KLK5ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145835-A1 | Modulators of Alpha-4-beta-7 Integrin and MAdCAM | QUANTUM INTELLIGENCE CORP. (KR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145835-A1 | Modulators of Alpha-4-beta-7 Integrin and MAdCAM | ITGB7, ITGAM, ITGA4 | PLAU 793/4885KLKB1 1100/4885KLHL20 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.